Sierra quarterly reports3 Mar 2023 16:55
Sierra did acknowledge in their quarterly reports that SRA 737 might have greater earning potential further down the line but they decided to advance MOMO as it was nearer commercial status. Here is one of their quarterly extracts;
Because we have limited financial and managerial resources, we focus our research and development efforts on our product candidate, momelotinib. As a result, we may advertently or inadvertently forgo or delay pursuit of opportunities with other product candidates, including SRA737, that later prove to have greater commercial potential.
I still believe that this is true GLA